S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ISPC iSpecimen Inc

2.97

0.01 (0.34%)

21 Dec 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more iSpecimen Charts.

iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more iSpecimen Charts.

iSpecimen Inc News

Form 8-K - Current report
Saturday 21 December 2024 (11 hours ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Saturday 14 December 2024 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 14 December 2024 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 13 December 2024 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually
Thursday 7 November 2024 (1 month ago) • GlobeNewswire Inc.

iSpecimen Reports Third Quarter 2024 Results
Thursday 7 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 1 November 2024 (2 months ago) • Edgar (US Regulatory)

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
Friday 1 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 424B4 - Prospectus [Rule 424(b)(4)]
Thursday 31 October 2024 (2 months ago) • Edgar (US Regulatory)

iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
Wednesday 30 October 2024 (2 months ago) • GlobeNewswire Inc.

More iSpecimen Inc News Articles

AUD vs US Dollar

Westpac Banking

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions